Get the Stockscreener App
72.11
1.02%
0.73
Incyte Corp stock is traded at $72.11, with a volume of 1.30M.
It is up +1.02% in the last 24 hours and down -1.85% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$71.38
Open:
$71.66
24h Volume:
1.30M
Relative Volume:
0.72
Market Cap:
$13.96B
Revenue:
$4.08B
Net Income/Loss:
$32.48M
P/E Ratio:
515.07
EPS:
0.14
Net Cash Flow:
$16.80M
1W Performance:
+2.40%
1M Performance:
-1.85%
6M Performance:
+12.41%
1Y Performance:
+19.53%
1-Day Range:
$71.50
$72.97
1-Week Range:
$69.75
$72.97
52-Week Range:
$50.35
$83.95
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
72.11 | 13.96B | 4.08B | 32.48M | 16.80M | 0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Lobbying Update: $350,000 of INCYTE CORPORATION lobbying was just disclosed - Nasdaq
Incyte Corp. partners with Genesis Therapeutics to use AI for drug discovery - The Business Journals
Incyte and Genesis go boldly into AI-focused research - The Pharma Letter
Incyte joins the group getting guidance from AI’s Genesis - BioWorld Online
Incyte Secures Exclusive Rights In $30Mln AI Collaboration With Genesis Therapeutics - Nasdaq
Incyte partners with Genesis to discover new small molecule drugs - Investing.com
AI Meets Drug Discovery: Inside Incyte's $620M Genesis DealWill This Transform Pharma R&D? - StockTitan
Incyte to Present at Upcoming March 2025 Investor Conferences - BioSpace
Exclusive Healthcare Investor Access: Incyte's Double Conference Reveal Coming in March - StockTitan
Are Wall Street Analysts Bullish On Incyte Stock? - Barchart
Incyte's SWOT analysis: stock prospects amid patent cliff and pipeline potential - Investing.com
Are Wall Street Analysts Bullish on Incyte Stock? - Nasdaq
Incyte corp EVP Steven Stein sells shares worth $897,866 - MSN
Incyte jumps amid takeover speculation - MSN
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - MSN
Incyte (NASDAQ:INCY) Stock Rating Lowered by StockNews.com - MarketBeat
Incyte (NASDAQ:INCY) Price Target Raised to $77.00 at Stifel Nicolaus - MarketBeat
Incyte outlines 2025 milestones with projected $1B in incremental revenue contributions - MSN
abrdn plc Cuts Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte (NASDAQ:INCY) Trading Down 8.5% Following Weak Earnings - MarketBeat
State of Alaska Department of Revenue Has $1.26 Million Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Citigroup Issues Pessimistic Forecast for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
Stifel raises Incyte stock price target to $77 from $75 - MSN
Sumitomo Mitsui Trust Group Inc. Cuts Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte (NASDAQ:INCY) Issues Earnings Results - MarketBeat
Incyte stock falls 6% amid Q4 earnings, 2025 forecast - MSN
Incyte stock price target raised to $88 at TD Cowen - MSN
Cambiar Investors LLC Has $9.65 Million Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
JPMorgan Adjusts Incyte Price Target to $70 From $75, Maintains Neutral Rating -February 12, 2025 at 10:29 am EST - Marketscreener.com
Incyte backs out of immuno-oncology pact with Agenus - PharmaLive
Reevaluating Incyte Corporation After Earnings (Technical Analysis) - Seeking Alpha
Incyte Backs Out of Immuno-Oncology Pact With Agenus - BioSpace
Decoding Incyte Corp (INCY): A Strategic SWOT Insight - GuruFocus.com
Incyte Earnings: Strong Opzelura Sales; Focus on Expanding Portfolio Amid Jakafi Patent Expiration - Morningstar
Upcoming Patent Loss of Jakafi Highlights Portfolio Risks; Downgrading Incyte's Moat to None - Morningstar
Incyte's Revenue Beats Estimates Thanks To Jakafi And Opzelura - Finimize
Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics - MSN
Incyte (INCY) Stock Drops Amid Slower Growth Outlook - GuruFocus.com
Royal Bank of Canada Has Lowered Expectations for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
RBC cuts Incyte stock price target to $68 from $70 - Investing.com
Incyte Corporation (NASDAQ:INCY) Q4 2024 Earnings Call Transcript - Insider Monkey
What Analysts Are Saying About Incyte Stock - Benzinga
Citi cuts Incyte stock price target to $88, maintains buy rating - MSN
Jefferies Adjusts Price Target on Incyte to $81 From $84, Maintains Buy Rating -February 11, 2025 at 07:18 am EST - Marketscreener.com
Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Incyte’s Strong 2024 Financial Performance and Promising Outlook - MSN
Applovin, Incyte, Onsemi - TradingView
Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook - Yahoo Finance
Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook By GuruFocus - Investing.com Canada
Why Incyte (INCY) Shares Are Plunging Today - The Globe and Mail
Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):